Related Experiment Video

Updated: Nov 26, 2025

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.1K

Targeting PIM Kinases to Overcome Therapeutic Resistance in Cancer

Rachel K Toth1, Noel A Warfel2,3

  • 1University of Arizona Cancer Center, Tucson, Arizona.

Molecular Cancer Therapeutics
|December 11, 2020
PubMed

Insights

Proviral integration for Moloney murine leukemia virus (PIM) kinases drive cancer progression and therapeutic resistance. Targeting PIM kinases shows promise for improving cancer treatment efficacy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Uncontrolled activation of survival kinases, including PIM kinases, drives cancer progression and therapeutic resistance.
  • PIM kinases are oncogenic serine/threonine kinases crucial for tumorigenesis, regulating metabolism, proliferation, and survival.
  • PIM kinase activation is a significant factor in resistance to diverse anticancer therapies.

Purpose of the Study:

  • To review the signaling pathways utilized by PIM kinases in promoting cancer progression.
  • To explore the role of PIM kinases in therapeutic resistance across various cancer types.
  • To highlight biological contexts and strategies for targeting PIM kinases in cancer therapy.

Main Methods:

  • Literature review of preclinical and clinical studies on PIM kinase inhibitors.
  • Analysis of signaling pathways regulated by PIM kinases.
  • Examination of PIM kinase's role in cancer metastasis and drug resistance.

Main Results:

  • PIM kinases phosphorylate numerous substrates, influencing key cellular processes.
  • Pharmacologic inhibition of PIM kinases demonstrates potential to enhance standard and targeted cancer therapies.
  • PIM kinase activation is implicated in the progression and metastasis of multiple cancer types.

Conclusions:

  • PIM kinases are critical mediators of cancer progression and therapeutic resistance.
  • Targeting PIM kinases represents a promising therapeutic strategy to overcome treatment resistance.
  • Further research into PIM kinase signaling pathways can optimize its exploitation as an anticancer target.

More Related Videos

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.4K
Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

8.1K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.1K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.6K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.2K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.4K